Introduction of rituximab biosimilar cost saving in EU
CT-P10 was recently approved in the EU for all indications approved for branded rituximab (MabTHera), including chronic lymphocytic leukaemia(CLL), non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis. A budget impact analysis model was used to evaluate the budgetary impact of introducing CT-P10 into 28 EU member states for the treatment of rheumatoid....
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2017 |
|---|---|
| Enthalten in: |
PharmacoEconomics & outcomes news - (2017), 777, Seite 22 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
Budgets |
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1996366084 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1996366084 | ||
| 003 | DE-627 | ||
| 005 | 20230511181116.0 | ||
| 007 | tu | ||
| 008 | 170901s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20170901 |
| 035 | |a (DE-627)OLC1996366084 | ||
| 035 | |a (DE-599)GBVOLC1996366084 | ||
| 035 | |a (PRQ)proquest_journals_19248196030 | ||
| 035 | |a (KEY)0248955420170000000077700022introductionofrituximabbiosimilarcostsavingineu | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 070 |a 610 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 245 | 1 | 0 | |a Introduction of rituximab biosimilar cost saving in EU |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a CT-P10 was recently approved in the EU for all indications approved for branded rituximab (MabTHera), including chronic lymphocytic leukaemia(CLL), non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis. A budget impact analysis model was used to evaluate the budgetary impact of introducing CT-P10 into 28 EU member states for the treatment of rheumatoid... | ||
| 650 | 4 | |a Tax overpayment | |
| 650 | 4 | |a Corporate profiles | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Budgets | |
| 650 | 4 | |a VAT | |
| 650 | 4 | |a Cost control | |
| 773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics & outcomes news |d Auckland : Wolters Kluwer Health Adis, 1996 |g (2017), 777, Seite 22 |w (DE-627)193388901 |w (DE-600)1308910-9 |w (DE-576)435516213 |x 1173-5503 |7 nnns |
| 773 | 1 | 8 | |g year:2017 |g number:777 |g pages:22 |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1924819603 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |j 2017 |e 777 |h 22 | ||